JP7657548B2 - 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子 - Google Patents

獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子 Download PDF

Info

Publication number
JP7657548B2
JP7657548B2 JP2019556941A JP2019556941A JP7657548B2 JP 7657548 B2 JP7657548 B2 JP 7657548B2 JP 2019556941 A JP2019556941 A JP 2019556941A JP 2019556941 A JP2019556941 A JP 2019556941A JP 7657548 B2 JP7657548 B2 JP 7657548B2
Authority
JP
Japan
Prior art keywords
seq
polypeptide
il13r
il4r
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019556941A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517262A5 (https=
JP2020517262A (ja
Inventor
ハンチュン チャン，
ラム グエン，
フォーン チエン，
シー ジアン リー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elanco US Inc
Original Assignee
Elanco US Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elanco US Inc filed Critical Elanco US Inc
Publication of JP2020517262A publication Critical patent/JP2020517262A/ja
Publication of JP2020517262A5 publication Critical patent/JP2020517262A5/ja
Priority to JP2023028068A priority Critical patent/JP7776461B2/ja
Application granted granted Critical
Publication of JP7657548B2 publication Critical patent/JP7657548B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/7455—Thrombomodulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5406—IL-4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5437—IL-13

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019556941A 2017-04-21 2018-04-20 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子 Active JP7657548B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023028068A JP7776461B2 (ja) 2017-04-21 2023-02-27 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762488509P 2017-04-21 2017-04-21
US62/488,509 2017-04-21
PCT/US2018/028507 WO2018195388A1 (en) 2017-04-21 2018-04-20 Il4/il13 receptor molecule for veterinary use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023028068A Division JP7776461B2 (ja) 2017-04-21 2023-02-27 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子

Publications (3)

Publication Number Publication Date
JP2020517262A JP2020517262A (ja) 2020-06-18
JP2020517262A5 JP2020517262A5 (https=) 2021-05-27
JP7657548B2 true JP7657548B2 (ja) 2025-04-07

Family

ID=63856393

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019556941A Active JP7657548B2 (ja) 2017-04-21 2018-04-20 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子
JP2023028068A Active JP7776461B2 (ja) 2017-04-21 2023-02-27 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023028068A Active JP7776461B2 (ja) 2017-04-21 2023-02-27 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子

Country Status (11)

Country Link
US (2) US11970526B2 (https=)
EP (1) EP3612555A4 (https=)
JP (2) JP7657548B2 (https=)
KR (2) KR20200006528A (https=)
CN (1) CN110770250B (https=)
AU (2) AU2018254542B2 (https=)
BR (1) BR112019021812A2 (https=)
CA (1) CA3059731A1 (https=)
MX (1) MX2019012570A (https=)
NZ (1) NZ757956A (https=)
WO (1) WO2018195388A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102460040B1 (ko) 2016-04-27 2022-11-01 애브비 인코포레이티드 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
US11970526B2 (en) 2017-04-21 2024-04-30 Elanco Us Inc. IL4/IL13 receptor molecule for veterinary use
BR112020002871A2 (pt) * 2017-08-15 2020-07-28 Kindred Biosciences, Inc. variantes fc de igg para uso veterinário
US12428466B2 (en) 2018-10-25 2025-09-30 Elanco Us Inc. IL4/IL13 receptor molecule for veterinary use
CN113710229B (zh) 2019-02-25 2026-01-06 芝加哥大学 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物
BR112022021204A2 (pt) * 2020-04-22 2022-12-06 Kindred Biosciences Inc Polipeptídeos, proteínas heterodiméricas, ácido nucleico, células hospedeiras, método, composição farmacêutica e método de tratamento de uma espécie de animal de companhia, métodos para reduzir a atividade de sinalização de il13 e/ou il4 e para detectar il13 ou il4 em uma amostra
EP4165066A4 (en) * 2020-06-12 2024-08-14 Beijing Vdjbio Co., Ltd. FUSION POLYPEPTIDE
MX2024002149A (es) 2021-08-20 2024-03-08 Intervet Int Bv Proteinas de fusion para tratar la dermatitis atopica.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007161724A (ja) 2003-12-23 2007-06-28 Tanox Inc 新規抗ｉｌ１３抗体およびその使用
JP2008504806A (ja) 2004-02-27 2008-02-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ−４／ｉｌ−１３特異的ポリペプチドおよびその治療上の使用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US7253264B1 (en) 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
US5470952A (en) 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5705154A (en) 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US6428788B1 (en) 1995-03-15 2002-08-06 Penn State University Compositions and methods for specifically targeting tumors
US7078494B1 (en) 1996-03-01 2006-07-18 Genetics Institute, Llc Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6743604B1 (en) 1996-12-13 2004-06-01 Smithkline Beecham Corporation Substances and their uses
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US7083949B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
PT1141286E (pt) 1998-12-14 2007-01-31 Genetics Inst Llc Cadeia de receptores de citocina
US6846486B1 (en) 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
WO2001077332A2 (en) 2000-04-07 2001-10-18 Heska Corporation Compositions and methods related to canine igg and canine il-13 receptors
EP2990420B1 (en) 2000-05-26 2016-12-21 Immunex Corporation Use of interleukin-4 receptor antibodies and compositions thereof
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
WO2005032399A2 (en) 2003-05-30 2005-04-14 The Regents Of The University Of California Il4 receptor antagonists for horse, dog and cat
CN1922204A (zh) 2004-02-27 2007-02-28 瑞泽恩制药公司 Il－4/il－13特异性的多肽和其治疗应用
US8354109B2 (en) 2005-12-13 2013-01-15 Suppremol Gmbh Multimeric Fc receptor polypeptides
EP2674440B1 (en) * 2005-12-16 2019-07-03 IBC Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
WO2008073463A2 (en) * 2006-12-11 2008-06-19 Wyeth Methods and compositions for treating and monitoring treatment of il-13-associated disorders
WO2009061911A1 (en) * 2007-11-06 2009-05-14 Wyeth Assays and methods for evaluating multimeric complexes
EP2220125A4 (en) 2007-11-13 2010-12-29 Sapphire Energy Inc PRODUCTION OF FC HYBRID POLYPEPTIDES IN EUKARYOTIC ALGAE
EP2702069A4 (en) 2011-04-29 2015-04-29 Janssen Biotech Inc IL4 / IL13 BINDING REPEAT PROTEINS AND USES THEREOF
ES2710384T3 (es) * 2011-12-13 2019-04-24 Pieris Pharmaceuticals Gmbh Procedimientos para la prevención o el tratamiento de determinados trastornos mediante la inhibición de la unión de IL-4 y/o IL-13 a sus respectivos receptores
EP2850093B1 (en) * 2012-01-27 2019-01-09 The Board of Trustees of the Leland Stanford Junior University Therapeutic il-13 polypeptides
JP6306588B2 (ja) 2012-08-21 2018-04-04 サノフィ・バイオテクノロジー Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
AU2016239858B2 (en) 2015-04-02 2021-07-01 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
EA201890391A1 (ru) * 2015-07-29 2018-08-31 НАНОТИКС, ЭлЭлСи Модульные композиции для утилизации растворимых биомолекул и связанные с этим способы
CN118307682A (zh) 2016-09-27 2024-07-09 埃皮辛特瑞柯斯公司 免疫调节性融合蛋白
US11970526B2 (en) 2017-04-21 2024-04-30 Elanco Us Inc. IL4/IL13 receptor molecule for veterinary use
US12428466B2 (en) 2018-10-25 2025-09-30 Elanco Us Inc. IL4/IL13 receptor molecule for veterinary use
BR112022021204A2 (pt) 2020-04-22 2022-12-06 Kindred Biosciences Inc Polipeptídeos, proteínas heterodiméricas, ácido nucleico, células hospedeiras, método, composição farmacêutica e método de tratamento de uma espécie de animal de companhia, métodos para reduzir a atividade de sinalização de il13 e/ou il4 e para detectar il13 ou il4 em uma amostra

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007161724A (ja) 2003-12-23 2007-06-28 Tanox Inc 新規抗ｉｌ１３抗体およびその使用
JP2008504806A (ja) 2004-02-27 2008-02-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ−４／ｉｌ−１３特異的ポリペプチドおよびその治療上の使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
" Full=Uncharacterized protein {ECO:0000313|Ensembl:ENSCAFP00000030717};GNName=IL13RA1 {ECO:0000313, 2017年03月15日, 掲載日, https://www.uniprot.org/uniprot/E2QZ78.txt?version=38
" Full=Uncharacterizedprotein {ECO:0000313|Ensembl:ENSCAFP00000025718};GN Name=IL4R {ECO:0000313|En, 2017年03月15日, 発行日, https://www.uniprot.org/uniprot/E2RFN6.txt?version=43

Also Published As

Publication number Publication date
JP2023078158A (ja) 2023-06-06
EP3612555A4 (en) 2020-12-30
US20200048325A1 (en) 2020-02-13
EP3612555A1 (en) 2020-02-26
AU2018254542A1 (en) 2019-11-21
WO2018195388A1 (en) 2018-10-25
CN110770250B (zh) 2025-01-07
US20240270820A1 (en) 2024-08-15
AU2023201726B2 (en) 2024-11-21
AU2023201726A1 (en) 2023-04-27
KR20200006528A (ko) 2020-01-20
RU2019137211A (ru) 2021-05-21
US11970526B2 (en) 2024-04-30
JP2020517262A (ja) 2020-06-18
JP7776461B2 (ja) 2025-11-26
CA3059731A1 (en) 2018-10-25
CN110770250A (zh) 2020-02-07
BR112019021812A2 (pt) 2020-05-26
RU2019137211A3 (https=) 2021-09-09
AU2018254542B2 (en) 2022-12-22
KR20250057131A (ko) 2025-04-28
NZ757956A (en) 2026-02-27
MX2019012570A (es) 2019-12-02

Similar Documents

Publication Publication Date Title
JP7776461B2 (ja) 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子
US12428466B2 (en) IL4/IL13 receptor molecule for veterinary use
JP7821741B2 (ja) 動物用のｉｌ４／ｉｌ１３受容体分子
US20220169740A1 (en) NGF Antagonists for Medical Use
JP7671275B2 (ja) 動物用の抗ｉｌ３１抗体
US12583917B2 (en) IL17A antibodies and antagonists for veterinary use
JP2023506923A (ja) イヌインターロイキン－４受容体α抗体
RU2795591C2 (ru) Молекула рецептора il4/il13 для ветеринарного применения
RU2829812C2 (ru) Антагонисты ngf для медицинского использования
KR20200057701A (ko) 수의과용 igg fc 변이체

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210416

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210416

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220715

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230227

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230227

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230314

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230425

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230602

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20231124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250124

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250326

R150 Certificate of patent or registration of utility model

Ref document number: 7657548

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150